Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
99 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Interleukin 1 (IL1) - Pipeline Review, H1 2017 Summary Interleukin 1 (IL1) pipeline Target constitutes close to 28 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Interleukin 1 (IL1) - Pipeline Review, H1 2017, outlays comprehensive information on the Interleukin 1 (IL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Interleukin 1 (IL1) - Interleukin-1 is a cytokine which plays an important role regulation of immune and inflammatory responses. It helps leukocytes pass through blood vessel walls to sites of infection and causes fever by affecting areas of the brain that control body temperature. There are two forms of interleukin-1, alpha and beta. IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 9, 2, 11 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Dermatology, Musculoskeletal Disorders, Immunology, Metabolic Disorders, Cardiovascular, Oncology, Central Nervous System, Genetic Disorders, Ear Nose Throat Disorders, Gastrointestinal and Genito Urinary System And Sex Hormones which include indications Gouty Arthritis (Gout), Acne Vulgaris, Epidermolysis Bullosa, Inflammation, Atherosclerosis, Behcet Disease, Familial Mediterranean Fever, Non-Small Cell Lung Cancer, Rheumatoid Arthritis, Type 2 Diabetes, Alzheimer's Disease, Autoimmune Disorders, Bladder Cancer, Cardiovascular Risk Factors, Colorectal Cancer, Dermatological Disorders, Diabetes, Esophageal Cancer, Fallopian Tube Cancer, Hearing Disorders, Hidradenitis Suppurativa, Hypercholesterolemia, Kidney Fibrosis, Liver Fibrosis, Lymphoma, Metastatic Colorectal Cancer, Mevalonate Kinase Deficiency (Hyperimmunoglobulin D Syndrome (HIDS)), Muckle-Wells Syndrome, Myocardial Infarction, Neonatal Onset Multisystem Inflammatory Disease, Osteoarthritis, Ovarian Cancer, Pain, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Restenosis, Sarcoidosis, Skin Inflammation, Systemic Idiopathic Juvenile Arthritis and Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (Familial Hibernian Fever). Furthermore, this report also reviewsalso reviews key players involved in Interleukin 1 (IL1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Interleukin 1 (IL1) - The report reviews Interleukin 1 (IL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Interleukin 1 (IL1) targeted therapeutics and enlists all their major and minor projects - The report assesses Interleukin 1 (IL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Interleukin 1 (IL1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Interleukin 1 (IL1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Interleukin 1 (IL1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Interleukin 1 (IL1) - Overview Interleukin 1 (IL1) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Interleukin 1 (IL1) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Interleukin 1 (IL1) - Companies Involved in Therapeutics Development AbbVie Inc Anacor Pharmaceuticals Inc Apexigen Inc Cell Medica Ltd Exicure Inc Immune Response BioPharma Inc Novartis AG Omnitura Therapeutics Inc Opsona Therapeutics Ltd Optimum Therapeutics LLC Orphit SAS Peptinov SAS R Pharm Regeneron Pharmaceuticals Inc Swedish Orphan Biovitrum AB TWi Biotechnology Inc XBiotech Inc Interleukin 1 (IL1) - Drug Profiles ABT-981 - Drug Profile Product Description Mechanism Of Action R&D Progress AC-203 - Drug Profile Product Description Mechanism Of Action R&D Progress AN-4161 - Drug Profile Product Description Mechanism Of Action R&D Progress Antisense Oligonucleotide to Inhibit IL-1 Beta for Epidermolysis Bullosa - Drug Profile Product Description Mechanism Of Action R&D Progress APX-002 - Drug Profile Product Description Mechanism Of Action R&D Progress canakinumab - Drug Profile Product Description Mechanism Of Action R&D Progress CV-18C3 - Drug Profile Product Description Mechanism Of Action R&D Progress diacerein - Drug Profile Product Description Mechanism Of Action R&D Progress diacerein CR - Drug Profile Product Description Mechanism Of Action R&D Progress DLX-2323 - Drug Profile Product Description Mechanism Of Action R&D Progress DLX-2681 - Drug Profile Product Description Mechanism Of Action R&D Progress IR-1000 - Drug Profile Product Description Mechanism Of Action R&D Progress IR-1002 - Drug Profile Product Description Mechanism Of Action R&D Progress IR-888 - Drug Profile Product Description Mechanism Of Action R&D Progress MABp-1 - Drug Profile Product Description Mechanism Of Action R&D Progress melittin - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis - Drug Profile Product Description Mechanism Of Action R&D Progress OMN-54 - Drug Profile Product Description Mechanism Of Action R&D Progress PPV-01 - Drug Profile Product Description Mechanism Of Action R&D Progress RA-18C3 - Drug Profile Product Description Mechanism Of Action R&D Progress rilonacept - Drug Profile Product Description Mechanism Of Action R&D Progress RPH-104 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis - Drug Profile Product Description Mechanism Of Action R&D Progress SOBI-006 - Drug Profile Product Description Mechanism Of Action R&D Progress suramin hexasodium - Drug Profile Product Description Mechanism Of Action R&D Progress T-218C3 - Drug Profile Product Description Mechanism Of Action R&D Progress Xilonix - Drug Profile Product Description Mechanism Of Action R&D Progress Ymalzen - Drug Profile Product Description Mechanism Of Action R&D Progress Interleukin 1 (IL1) - Dormant Products Interleukin 1 (IL1) - Discontinued Products Interleukin 1 (IL1) - Product Development Milestones Featured News & Press Releases Jun 01, 2017: XBiotech Presents Phase III Findings for its Antibody Therapy for Colorectal Cancer at the 2017 ASCO Meeting May 30, 2017: Dr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal Cancer Apr 20, 2017: XBiotech Announces Outcome of EMA's Oral Explanation Meeting Mar 06, 2017: Castle Creek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for Diacerein 1% Ointment in Treatment of Epidermolysis Bullosa Simplex Feb 22, 2017: XBiotech Completes Dosing of Subjects in PK Study Being Conducted in Connection with European Marketing Application Feb 21, 2017: Xbiotech Reports Affirmative Interim Analysis Of Global Phase 3 Colorectal Cancer Study Feb 16, 2017: XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa Jan 17, 2017: XBiotech Phase 3 Data for Colorectal Cancer Therapy is Published in The Lancet Oncology Dec 16, 2016: Novartis receives positive CHMP recommendation for Ilaris to treat rare diseases in adults and children called Periodic Fever Syndromes Dec 07, 2016: XBiotech Completes Enrollment in Global Phase III Study using Xilonix Monotherapy to Treat Advanced Colorectal Cancer Oct 12, 2016: Xbiotech Announces Successful Completion of EMA GMP Inspection Oct 01, 2016: Castle Creek Pharmaceuticals Announces Late-Breaking Results at EADV of Phase 2 Topical Diacerein 1% Data in Patients with Epidermolysis Bullosa Simplex Sep 23, 2016: Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions Jul 22, 2016: XBiotech Provides Update on Xilonix Phase III Programs in US and EU Jul 14, 2016: The Debate on the Phase 3 Trial of MABp1 Presented at the 18th ESMO World Congress of Gastrointestinal Cancer Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by AbbVie Inc, H1 2017 Pipeline by Anacor Pharmaceuticals Inc, H1 2017 Pipeline by Apexigen Inc, H1 2017 Pipeline by Cell Medica Ltd, H1 2017 Pipeline by Exicure Inc, H1 2017 Pipeline by Immune Response BioPharma Inc, H1 2017 Pipeline by Novartis AG, H1 2017 Pipeline by Omnitura Therapeutics Inc, H1 2017 Pipeline by Opsona Therapeutics Ltd, H1 2017 Pipeline by Optimum Therapeutics LLC, H1 2017 Pipeline by Orphit SAS, H1 2017 Pipeline by Peptinov SAS, H1 2017 Pipeline by R Pharm, H1 2017 Pipeline by Regeneron Pharmaceuticals Inc, H1 2017 Pipeline by Swedish Orphan Biovitrum AB, H1 2017 Pipeline by TWi Biotechnology Inc, H1 2017 Pipeline by XBiotech Inc, H1 2017 Dormant Products, H1 2017 Dormant Products, H1 2017 (Contd..1), H1 2017 Dormant Products, H1 2017 (Contd..2), H1 2017 Dormant Products, H1 2017 (Contd..3), H1 2017 Dormant Products, H1 2017 (Contd..4), H1 2017 Discontinued Products, H1 2017 Discontinued Products, H1 2017 (Contd..1), H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
